Avidity Biosciences, Inc., a biopharmaceutical company based in San Diego, California, is at the forefront of developing RNA therapeutics designed to treat diseases previously untreatable with RNA-based approaches. The company specializes in the creation of antibody oligonucleotide conjugates (AOC), a novel class of therapeutics that combine the specificity of antibodies with the therapeutic potential of oligonucleotides.
- AOC 1001: The company's lead product candidate, AOC 1001, is currently undergoing phase 1/2 clinical trials for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease. This represents a significant step forward in addressing a condition with limited treatment options.
- AOC 1044: Another promising candidate, AOC 1044, is in development for duchenne muscular dystrophy, also in phase 1/2 clinical trials. This product aims to offer a new therapeutic avenue for patients suffering from this debilitating condition.
- AOC 1020: Additionally, AOC 1020 is being developed to treat facioscapulohumeral muscular dystrophy, with clinical trials also in the phase 1/2 stage. This underscores Avidity Biosciences' commitment to tackling rare skeletal muscle diseases.
Founded in 2012, Avidity Biosciences has rapidly grown to become a key player in the biotechnology sector, focusing on rare skeletal muscle and rare cardiac diseases. The company's innovative approach to RNA therapeutics has the potential to significantly impact the treatment landscape for these challenging conditions.
With a market capitalization of $3.6 billion and a dedicated team of 253 full-time employees, Avidity Biosciences continues to push the boundaries of medical science, aiming to bring hope and improved quality of life to patients with rare diseases.
